— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year.
— Net loss was $21.5 million compared to $20.4 million last year.
— Research and development expenses were $15.5 million versus $16.9 million for 2018.
— Cash and cash equivalents as of December 31, 2019, totaled $22.7 million, compared to $17 million as of December 31, 2018.
Most Popular
CCL Earnings: Highlights of Carnival Corporation’s Q4 2025 results
Cruise operator Carnival Corporation & plc (NYSE: CCL) on Friday reported an increase in revenue and adjusted earnings for the fourth quarter of fiscal 2025. Earnings topped analysts' expectations. Revenues
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
